Stathopoulou et al., 2025 - Google Patents
Temporal mapping of the anti-tumor effects of nanobody-based MSLN. CAR-T cell therapy in metastatic solid tumorsStathopoulou et al., 2025
View HTML- Document ID
- 16756775699819733420
- Author
- Stathopoulou C
- Zhao M
- Jiang Q
- Hong J
- Bian J
- Zhang J
- Ho M
- Hassan R
- Publication year
- Publication venue
- bioRxiv
External Links
Snippet
Studies on the dynamic changes occurring in the tumor microenvironment (TME) following CAR-T cell therapy have been confounded by host lymphodepletion, multiple dosing and immunodeficient models. Here, a nanobody-based, mouse mesothelin-targeting CAR-T cell …
- 230000000259 anti-tumor effect 0 title abstract description 12
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaczanowska et al. | Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis | |
| Gulhati et al. | Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer | |
| ES3042082T3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
| Baharom et al. | Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment | |
| Liu et al. | Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution | |
| Hu et al. | TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma | |
| Schaafsma et al. | VISTA targeting of T-cell quiescence and myeloid suppression overcomes adaptive resistance | |
| Song et al. | Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy | |
| WO2017048614A1 (en) | Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood | |
| Pimenta et al. | IRF5 is a novel regulator of CXCL13 expression in breast cancer that regulates CXCR5+ B‐and T‐cell trafficking to tumor‐conditioned media | |
| EP3512537B1 (en) | T-cell immunotherapy | |
| WO2020095044A1 (en) | Monocytes for cancer targeting | |
| Kazakova et al. | Interaction of tumor-associated macrophages with stromal and immune components in solid tumors: Research progress | |
| Wang et al. | Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death | |
| KR20220157435A (en) | Method for Isolating T Cells and T Cell Receptors from Tumors by Single Cell Assay for Immunotherapy | |
| Suresh et al. | MIF confers survival advantage to pancreatic CAFs by suppressing interferon pathway‐induced p53‐dependent apoptosis | |
| Li et al. | Intraperitoneal infusion of NKG2D CAR-NK cells induces endogenous CD8+ T cell activation in patients with advanced colorectal cancer | |
| US20240201192A1 (en) | Folr2+ macrophages and anti-tumor immunity | |
| Gryziak et al. | The role of tumor‐associated macrophages in hepatocellular carcinoma—from bench to bedside: a review | |
| Stathopoulou et al. | Temporal mapping of the anti-tumor effects of nanobody-based MSLN. CAR-T cell therapy in metastatic solid tumors | |
| Li et al. | Overexpression of FBP1 enhances dendritic cell activation and maturation by inhibiting glycolysis and promoting the secretion of IL33 in lung adenocarcinoma | |
| WO2024052433A1 (en) | Identification of a common precursor to effector and regulatory tissue imprinted cd4+ t cells and therapeutic use thereof | |
| Loffredo et al. | An amphiregulin reporter mouse enables transcriptional and clonal expansion analysis of reparative lung Tregs | |
| Williams et al. | Isolation and expansion of murine γδ T cells from mouse splenocytes | |
| Tsai et al. | Senescent tumoral HLA-E reshapes microenvironment through impairing NK cell-dendritic cell-T cell network in malignant pleural effusion from lung cancer |